Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing itself at it
The model's full reasoning — Q4 2017 call → NOWe need to determine if management describes an identifiable offering with both: (1) customer response running ahead of what company prepared for, and (2) company responding now by putting more behind it. Also offering is small relative to total business. Scan transcript for such descriptions. Key candidates: OptumCare, DaVita Medical Group, Rally, PreCheck MyScript, Nexus ACO, Motion Wellness, MedExpress-Walgreens, etc. Look for language indicating demand exceeding preparation and current expansion. - MedExpress-Walgreens: "we have about a dozen or so locations that we brought online throughout 2017 and that was really to see whether not a retail side of service... The results are not near final but we’re hoping that our MedExpress surgical care model with an adjunct pharmacy performs as good or better..." This is about testing, not demand ahead. - Rally: "We doubled the number of people with Rally IDs in 2017, now more than 15 million... Market interest for this type of scale tested solution is growing." No mention of exceeding preparation. - PreCheck MyScript: "has already being used by tens of thousands of prescribers for nearly 1.5 million transactions. We will offer it to all OptumRx members expecting to reach 80% of active prescribers by the end of 2019." This is rollout, but no indication of demand exceeding preparation. - OptumCare with DaVita: "Combined with DMG, OptumCare will be in 35 local care delivery markets, nearly one-half of the 75 markets targeted for engagement or development." This is expansion but not described as response to demand exceeding preparation. - Nexus ACO: "We expanded into several new markets... And we’ll enter Minnesota and the northern planes in the second half of 2018." No mention of demand ahead. - Motion Wellness: "Participants... have used activity trackers to walk 65 million miles, earning nearly $20 million in incentives." No mention of exceeding preparation. - Behavioral health: "we’ve had strong performance across the board... we continue to ramp up and add external customers and grow in virtually each of the segments that we serve." No specific demand ahead. - OptumRx: "strong increase in adjusted scripts... our script growth was the highest in Q4 versus any other quarter in the year." That's just strong performance, not necessarily ahead of preparation.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
HCKT · Q1 2024 → YESThe question is about whether management describes one identifiable offering that's still small, where customer response is ahead of what they prepared for, AND they're responding now by putting more ...YES The transcript describes AI Explorer (the GenAI assessment platform) as a small, early-stage offering (nominal Q1 revenue impact, part of broader GenAI pivot). Management states customer response is exceeding preparation: "over 175 demo meetings with many more scheduled... resulted in a number of new enterprise...
SYY · Q1 2023 → YESThe question is about whether management describes one identifiable offering or initiative that's still a smaller part of the business, where customer response is running ahead of what they prepared f...YES The transcript shows that Sysco Your Way is presented as a smaller, still-developing offering (described as part of the Recipe For Growth pillars, with its scale expected to grow each quarter and currently limited to specific neighborhoods and recent international rollouts like Toronto and Dublin).
PRPH · Q1 2023 → YESThe question asks if management describes one identifiable offering that's still a smaller part of the business, where customer response is running ahead of what they prepared for, AND they're respond...YES The lozenge manufacturing facility is the clearest match. It is explicitly described as “the least interesting business we’re developing” and still a smaller slice of overall results (COVID testing was the dominant revenue driver for the prior two years).